Introduction
============

Concurrent irinotecan and fluorinated-pyrimidine is a common first-line therapy for metastatic colorectal cancer (mCRC) ([@b1-ijo-45-04-1381]--[@b6-ijo-45-04-1381]). Although prolonged survival is associated with regimens involving irinotecan, severe neutropenia occurs in 20--35% of mCRC cases treated with irinotecan regimens. Carboxylesterases catabolized irinotecan to 7-ethyl-10-hydroxycamptothecin (SN-38), which is a potent topoisomerase I inhibitor ([@b7-ijo-45-04-1381],[@b8-ijo-45-04-1381]). SN-38 is then further catabolized by hepatic uridin diphosphate-glucuronosyltransferase (UGT) 1A enzymes to an inactive SN-38 glucuronide (SN-38G) ([@b9-ijo-45-04-1381]). Many mCRC patients with a genetic variant (*UGT1A1\*28*) experience severe irinotecan toxicity; *UGT1A1\*28* is a variation in the number (seven vs. six) of TA repeats in the promoter region of *UGT1A1* ([@b10-ijo-45-04-1381],[@b11-ijo-45-04-1381]). Interestingly, the toxicity and tumor response of concurrent leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI) reportedly also correlate with *UGT1A* variants (*UGT1A1*, *UGT1A7* and *UGT1A9*) and haplotypes including these variants ([@b12-ijo-45-04-1381]--[@b18-ijo-45-04-1381]). There are differences between Caucasian and Asian populations in frequencies of *UGT1A* variants, and *UGT1A1\*6* reportedly associates strongly with severe neutropenia especially among Asian patients ([@b12-ijo-45-04-1381],[@b17-ijo-45-04-1381]).

To predict the risk of irinotecan toxicity for individual patients, it is important that determining the relative contributions of *UGT1A* variants other than *UGT1A1\*28* and *UGT1A1\*6* is important to the development of any system designed to predict irinotecan toxicity for individual patients because patients without *UGT1A1\*28* or *\*6* do experience severe irinotecan toxicity. Several studies have examined associations between irinotecan toxicity and *UGT1A* haplotypes in addition to each genotype of *UGT1A* ([@b17-ijo-45-04-1381]--[@b19-ijo-45-04-1381]). However, determining the haplotype or diplotype for each patient is difficult; moreover, most haplotypes and diplotypes are too rare to constitute a group large enough for meaningful statistical analysis. Moreover, gender and age of patients each reportedly have an impact on irinotecan toxicity ([@b20-ijo-45-04-1381]--[@b22-ijo-45-04-1381]). Hence, these factors should be also taken into consideration when developing a system designed to predict irinotecan toxicity.

The aim of this study was to evaluate whether the combinations of *UGT1A* genotypes, but not haplotypes, together with patient characteristics might be useful in predicting the risk to patients with mCRC treated of irinotecan-containing regimens. Here, we investigated the genotypes of 123 patients at six loci: *UGT1A1\*6* (211G\>A, rs4148323), *UGT1A1\*28* (TA~6~\>TA~7~, rs8175347), *UGT1A1\*60* (−3279T\>G, rs4124874), *UGT1A7* (387T\>G, rs17868323), *UGT1A7* (622T\>C, rs11692021), and *UGT1A9\*1b* (−118T~9~\>T~10~, rs35426722, also called *UGT1A9\*22*) ([@b23-ijo-45-04-1381]). Next, we evaluated the contribution of each *UGT1A* genotype, haplotype, and diplotype to the risk of irinotecan toxicity. Furthermore, we developed a new system for predicting the risk that a patient will experience irinotecan toxicity; this system uses sequential forward floating selection (SFFS) algorithm based on statistical pattern recognition to select the combinations of *UGT1A* genotypes, gender and age. SFFS is a sequential search method characterized by a dynamically changing number of features included or eliminated at each step of an individual analysis ([@b24-ijo-45-04-1381]). This is the first study conducted to assess the role of the combination of genotypes at six polymorphic sites in *UGT1A* and clinical features constructed by SFFS on the risk of irinotecan toxicity.

Materials and methods
=====================

Patients
--------

In this study, 123 mCRC patients were examined for association between *UGT1A* genotypes and irinotecan toxicity ([Table I](#tI-ijo-45-04-1381){ref-type="table"}). This study was performed as an ancillary investigation; data collected from three prospective studies \[FLIGHT1 ([@b5-ijo-45-04-1381]), FLIGHT2 ([@b5-ijo-45-04-1381]) and FRUTIRI ([@b6-ijo-45-04-1381])\] and from consecutive patients who received FOLFIRI at the Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Japan. Each participant received irinotecan at the dose of 150 mg/m^2^, which has been approved in Japan.

FLIGHT1 (UMIN000002388) and FLIGHT2 (UMIN000002476) were phase II studies of first line and second line chemotherapy, respectively, for mCRC. Study designs and key eligibility and exclusion criteria have been described in detail ([@b5-ijo-45-04-1381],[@b25-ijo-45-04-1381],[@b26-ijo-45-04-1381]). Briefly, each regimen consisted of irinotecan on day 1 +400 mg/m^2^ fluorouracil bolus followed by 2,400 mg/m^2^ fluorouracil continuous infusion during 46 h + 200 mg/m^2^ leucovorin on day 1 every 2 weeks. Of all patients from the FLIGHT1 and FLIGHT2 studies, 38 and 35, respectively, participated in this ancillary investigation and use; these 73 patients constituted the training population. FLIGHT1 or FLIGHT2 patients homozygous for *UGT1A1\*28* were excluded from the training population because these patients received a lower starting dose of irinotecan (100 mg/m^2^) ([@b5-ijo-45-04-1381]).

The validation population comprised 50 patients from two different study groups: 22 patients who participated in FRUTIRI (UMIN000005011), a phase II study of a combination therapy comprised irinotecan and 5′-deoxy-5-fluorouridine (5′-DFUR) ([@b6-ijo-45-04-1381]) and 28 consecutive patients who underwent second-line FOLFILI treatment between October, 2008 and July, 2012 in the Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Japan. Detail treatment regimen tested in FRUTIRI was described previously ([@b6-ijo-45-04-1381]). Briefly, irinotecan was administered every two weeks, and 400 mg 5′-DFUR was administered every week orally twice a day on five consecutive days that were followed by a weekly 2-day washout. The 28 consecutive patients undergoing FOLFIRI treatment were following the protocol used in FLIGHT2 ([@b26-ijo-45-04-1381]). In a validation population, patients with *UGT1A1\*28* homozygous were not found in the FRUTIRI study (n=28). Additionally, patients heterozygous for *UGT1A1\*28* (n=6) were excluded from the FRUTIRI study because these patients received lower starting dose of irinotecan 70 mg/m^2^. Among the 28 consecutive patients who received second-line FOLFILI therapy, homozygous for *UGT1A1\*6* or *\*28* and those compound heterozygous for *UGT1A1\*6* and *UGT1A1\*28* been excluded from this ancillary study. The training (n=73) and validation (n=50) populations did not differ significantly with regard to the distribution of any clinical feature or genotype that is listed in [Table I](#tI-ijo-45-04-1381){ref-type="table"} except for the distributions of the *UGT1A7* (*387T*\>*G*) and *UGT1A9\*1b* alleles (data not shown).

In this study, we defined patients who exhibited hematologic toxicity greater than grade 3 during the entire course of therapy as experiencing irinotecan toxicity. The study protocols were approved by the Institutional Review Board at Yamaguchi University Graduate School of Medicine, and were carried out in accordance with the Helsinki declaration on experimentation on human subjects. Each patient gave written, informed consent for their participation in this study.

Genotyping of UGT1A and haplotype construction
----------------------------------------------

A conventional sodium iodide (NaI) method was used to extract genomic DNA from peripheral blood samples ([@b27-ijo-45-04-1381]). The number of TA repeats in the *UGT1A1* promoter region was determined by the fragment size analysis followed by direct sequencing as described previously ([@b4-ijo-45-04-1381]). The TaqMan technique with a hydrolysis probe was used to determine the *UGT1A1\*6* genotype as described previously ([@b28-ijo-45-04-1381]); similarly, hydrolysis probes were used to determine the genotypes at *UGT1A1\*60*; a direct sequencing method was also used to determine the genotypes at *UGT1A7* (387T\>G and 622T\>C) and *UGT1A9\*1b*.

Each nucleotide variant was evaluated to determine whether it was in Hardy-Weinberg equilibrium; Haploview 4.2 software was used to perform the linkage disequilibrium (LD) and case-control haplotype analyses ([@b29-ijo-45-04-1381]). Lewontin's coefficient D' and correlation coefficient *r*^2^ were calculated as measures of LD.

Construction of toxicity prediction system by genotype combinations
-------------------------------------------------------------------

To predict severe toxicities of irinotecan, the age, the gender and a comprehensive 6-site *UGT1A* genotype were determined for each of the 73 patients in the training population. SFFS, a method of statistical pattern recognition, was then used to determine the optimal genotype combinations for predicting the risk of irinotecan toxicity. The statistical pattern recognition, SFFS, identified the genotype combinations with the 'maximum number of cases' and 'maximum prediction rate' to maximize overall diagnostic accuracy ([@b24-ijo-45-04-1381]). Briefly, the algorithm of the SFFS used in this study was as follows: i) Suppose that at stage *k* we have a set of *X~1~*, ..., *X~k~* of sizes 1 to *k*, respectively. ii) Let the corresponding values of the feature selection criteria be *J~1~* to *J~k~*, where *J~i~* = *J*(*X~i~*), for the feature selection criterion *J*(.). iii) Let the total set of features be *X*. Then at the *k*th stage of the SFFS procedure follow these steps: Step 1, select the feature *x~j~* from *X*-*X~k~* that increases the value of *J* to the greatest degree and add it to the current set: *X*~(~*~k~* ~+\ 1)~ = *X~k~* + *x~j~*. Step 2, find the feature *x~r~* in the current set *X*~(~*~k~* ~+\ 1)~ that reduces the value of *J* the least; if this feature is the same as *x~j~* then set *J*~(~*~k~* ~+\ 1)~ = *J*(*X*~(~*~k~* ~+\ 1)~); increment *k*; go to step 1; otherwise remove it from the set to from *X*′*~k~* = *X*~(~*~k~* ~+\ 1)~ - *x~r~*. Step 3, continue removing features from the set *X*′*~k~* to form reduced sets *X*′ ~(~*~k~* ~−\ 1)~ while *J*(*X*′ ~(~*~k~* ~−\ 1)~) \> *J*~(~*~k~* ~−\ 1)~; *k* = *k* − 1; until *k* = 2; then continue with step 1. The algorithm is initialized by setting *k* = 0 and *X~0~* = Ø.

Statistical analysis
--------------------

Fisher's exact test was used to assess the relationship between toxicity and each *UGT1A* variant. The Cochran-Armitage trend test was used to examine the linearity of the relationship between *UGT1A* genotypes and irinotecan toxicity. SPSS Statics 17.0 software (IBM, Tokyo, Japan) and R version 2.13.0 software were used to perform the calculations ([@b30-ijo-45-04-1381]). p\<0.05 was considered statistically significant.

Results
=======

UGT1A allele and haplotype frequencies
--------------------------------------

The minor allele frequencies (MAF) of each *UGT1A* allele among the 103 patients without genetic bias; all patients regardless of the starting dose of irinotecan enrolled in FLIGHT1, FLIGHT2, and FRUTIRI studies, and 123 patients received a starting dose of 150 mg/m^2^ for case-control study participating in this study are listed in [Table II](#tII-ijo-45-04-1381){ref-type="table"}. In this study, the MAFs of *UGT1A1\*28* and *UGT1A1\*6* were approximately 0.117 and 0.184, respectively. The MAF for each other *UGT1A* SNP examined in this study was greater than 0.20. Among all patients, the Hardy-Weinberg equilibrium p-value for each locus examined in this study was higher than 0.05. LD analysis with 103 patients showed that high LD (*r*^2^\>0.9) was evident between *UGT1A7* (*387T*\>*G*) and *UGT1A9\*1b* ([Fig. 1](#f1-ijo-45-04-1381){ref-type="fig"}). We found 12 *UGT1A* haplotypes (*Hp-I* to *Hp-XII*) using 6 loci in 103 patients: *UGT1A1\*6*, *\*28*, *\*60*, *UGT1A7* (*387T*\>*G*), *UGT1A7* (*622T*\>*C*), and *UGT1A9\*1b* ([Table III](#tIII-ijo-45-04-1381){ref-type="table"}). Three common haplotypes (*Hp-I*, *Hp-II* and *Hp-III*) accounted for 82.5% of all haplotypes identified in this study.

Associations between UGT1A genotypes/haplotypes and irinotecan toxicity
-----------------------------------------------------------------------

We examined associations between individual *UGT1A* genotypes or haplotypes and severe irinotecan toxicity among 123 patients with mCRC who receive chemotherapy that included irinotecan ([Table IV](#tIV-ijo-45-04-1381){ref-type="table"}). Each of four *UGT1A* genotypes \[*UGT1A1\*6*, *UGT1A7* (*387T*\>*G*), *UGT1A7* (*622T*\>*C*) and *UGT1A9\*1b*\] showed a significant association to irinotecan toxicity and linear trend (p\<0.05). Similarly, two haplotypes (*Hp-I* and *Hp-II*) each showed a significant association to and linear trend with irinotecan toxicity (p\<0.05). Among two patients received a starting dose of 100 mg/m^2^ irinotecan, diplotype of *Hp-IV/V* did not show toxicity and diplotype of *Hp-V/V* showed toxicity. Six patients excluded from FRUTIRI study did not show toxicity of irinotecan (a starting dose of 70 mg/m^2^; *UGT1A* diplotypes of *Hp-I/V*, *II/IV* and *III/IV* were found in 2, 3 and 1 patients). Regarding non-hematological toxicities, only 5 patients developed grade 3 diarrhea (*UGT1A* diplotype of these 5 patients consists of 4 *Hp-I/II* and 1 *Hp-II/XII*).

Performances of the toxicity prediction system by genotype combination
----------------------------------------------------------------------

To construct a system for predicting the risk of severe irinotecan toxicity, genetic data from 73 patients that constituted the training population were analyzed exhaustively; specifically, SFFS was used to assess gender, age and the individual genotypes at six polymorphic *UGT1A* sites ([Fig. 2](#f2-ijo-45-04-1381){ref-type="fig"}). In addition to the three possible genotypes (wild-type homozygous, heterozygous, variant homozygous), a fourth option for each site (designated 'unspecified genotype') was included into the algorithm. Similarly, patient gender (male, female, regardless of gender) and age (≤60, \>60 years old, regardless of age) were assessed. The cutoff value for age (60 years) was determined by Youden index obtained by the receiver operating characteristic (ROC) curve analysis with the training population. Among possible combinations (4^6^ × 3^2^ − 1 = 36,863), the following cases were excluded: cases not found, single cases, and cases that represented positive or negative predictive values \<80%. In order to optimize the combinations, categorization according to predictive value and exclusion of redundant combinations in each category were performed. As a result, 8 combinations (P-I to P-VIII, [Fig. 1A](#f1-ijo-45-04-1381){ref-type="fig"}) appeared to predict an increased risk of toxicity, and 10 combinations (N-I to N-X, [Fig. 1B](#f1-ijo-45-04-1381){ref-type="fig"}) appeared to predict a lack of toxicity.

The system for predicting irinotecan toxicity based on combinations of 8 factors (6 genotypes, gender and age) was generated using data from of all 73 patients in the training population. The system was then applied to data from 84.9 and 86.0% of the patients in the training and validation populations, respectively ([Table V](#tV-ijo-45-04-1381){ref-type="table"}). This prediction system showed 83.9% accuracy (positive predictive value, 86.4%; negative predictive value, 82.5%) for the training population (n=62) and 72.1% accuracy (positive predictive value, 70.0%; negative predictive value, 72.7%) for the validation population (n=43). When patients who were not applied to the combinations were included, the performance of the system was 71.2% accuracy (sensitivity, 55.9%; specificity, 84.6%) in training population (n=73) and 62.0% accuracy (sensitivity, 41.2%; specificity, 72.7%) in validation population (n=50). Odds ratios of positive prediction for irinotecan toxicity for this prediction system were 8.0 (95% CI, 1.5--42.5) and 16.3 (95% CI, 2.2--121.4) in training and validation populations, respectively (p\<0.05, [Table VI](#tVI-ijo-45-04-1381){ref-type="table"}).

Patients with either of three *UGT1A* alleles \[*UGT1A1\*6*, *UGT1A7* (*622T*\>*C*) or *UGT1A9\*1b*\], *UGT1A haplotype-I* or *haplotype-II* showed significant association to severe irinotecan toxicity (p\<0.05) in both the training and validation populations (data not shown).

Discussion
==========

The novel system for predicting severe irinotecan toxicity described here was based on genotypes at 6 polymorphic sites in *UGT1A* and 2 basic clinical features; notably, it showed high predictive performance even though the treatment regimens differed among the training and validation patients ([Tables V](#tV-ijo-45-04-1381){ref-type="table"} and [VI](#tVI-ijo-45-04-1381){ref-type="table"}). The odds ratio of positive prediction for severe irinotecan toxicity was higher for this prediction system than for that of any other haplotype or for that of any genotype ([Table VI](#tVI-ijo-45-04-1381){ref-type="table"}). The performance of this prediction system was reduced from the 83.9% accuracy seen with applied patients to this system in the training population to 72.1% accuracy in the validation. With regard to positive prediction, the inconsistency in accuracy between training and validation populations was seen when the combinations included the *UGT1A9\*1b* site and patient age (P-II, VI and VII in [Fig. 2](#f2-ijo-45-04-1381){ref-type="fig"}). The frequencies of *UGT1A9\*1b* genotype differed between the training and validation populations; moreover, the *UGT1A9\*1b* alleles were not in Hardy-Weinberg equilibrium in the validation population (data not shown). The cutoff value for patient age (60 years old) was determined by a ROC curve generated with data from the training population; however, previous studies used a cutoff age of 65 years ([@b20-ijo-45-04-1381],[@b21-ijo-45-04-1381]). Indeed, one patient without toxicity, but predicted as presence of toxicity in this system, was aged 63 years.

Some genotypic combinations decreased the performance of negative prediction for sever irinotecan toxicity in the validation population relative to the training population (N-II, IV, and V in [Fig. 2](#f2-ijo-45-04-1381){ref-type="fig"}). Specifically, 36.4% (n=4/11) of patients in training population with a combined genotype that included heterozygous for *UGT1A1\*28* alleles and *UGT1A1\*6* (−*/*−) experienced severe irinotecan toxicity, but 66.7% (n=4/6) of the patients in validation population with the same genotype combinations (*UGT1A1\*6*, −*/*− and *UGT1A1\*28*, −/+) showed severe toxicity. Of the 73 patients in the training population and the 50 in the validation population, 11 (15.1%) and 7 (14.0%), respectively, were matched with neither of the combination in our prediction system. Interestingly, the incidence of severe toxicity among patients who were not matched with either combination identified by this prediction system was 72.7% (training population) and 14.3% (validation population) ([Table VI](#tVI-ijo-45-04-1381){ref-type="table"}). Therefore, the frequency of the irinotecan toxicity among patients who do not have any combination of *UGT1A* variants identified by this novel prediction system might be due to factors other than *UGT1A* polymorphisms.

Many published studies have focused on associations between irinotecan toxicity, irinotecan efficacy, or both and any one or more of each *UGT1A* variants examined here ([@b10-ijo-45-04-1381]--[@b19-ijo-45-04-1381],[@b31-ijo-45-04-1381],[@b32-ijo-45-04-1381]). Patients, especially Asian patients, homozygous for *UGT1A1\*6* or *\*28* or compound heterozygous for these variants are at high risk for hematologic toxicity ([@b13-ijo-45-04-1381],[@b33-ijo-45-04-1381],[@b34-ijo-45-04-1381]). In this study, each patient homozygous for *UGT1A1\*6* (n=3) and those compound heterozygous for *UGT1A1\*6* and *\*28* (n=3) showed severe hematologic toxicity; however, 45 patients of the remaining 117 patients still exhibited severe irinotecan toxicity. *UGT1A1\*6* and *\*28* each have strong effects on UGT1A1 activity and expression, but frequency of each allele is low; moreover, the frequencies of each allele differ between races ([@b11-ijo-45-04-1381],[@b14-ijo-45-04-1381],[@b35-ijo-45-04-1381]--[@b37-ijo-45-04-1381]). Among the patients that lacked these rare, highly effective variants, this novel prediction system could accurately predict whether there is severe irinotecan toxicity.

Here, as in previous studies, each identified *UGT1A* haplotypes was useful for precisely predicting the presence or absence of severe irinotecan toxicity ([@b14-ijo-45-04-1381],[@b18-ijo-45-04-1381],[@b38-ijo-45-04-1381]--[@b40-ijo-45-04-1381]). Consistent with our study, Cecchin *et al* reported that a haplotype comprising *UGT1A1\*28* (−), *UGT1A1\*60* (−), *UGT1A7* (*387T* and *622T*), and *UGT1A9\*1b* (+) was a predictor of severe hematologic toxicity during the entire course of therapy ([@b18-ijo-45-04-1381]). However, determining the haplotypes for any one patient is a difficult clinical measurement. Therefore, the genotypes at each of the 6 sites (rather than the haplotype or diplotype) could be used for clinical assessments.

Our prediction system depend not only on *UGT1A* genotypes but also on patient gender and age. Previous studies showed that patient gender and age were related to the risk of irinotecan toxicity ([@b20-ijo-45-04-1381]--[@b22-ijo-45-04-1381]). In the training population, patient age was associated with severe irinotecan toxicity, but patient gender was not ([Table IV](#tIV-ijo-45-04-1381){ref-type="table"}). Interestingly, when patient age, patient gender or both the patient age and gender were excluded from the factors used by the prediction system, the number of patients that matched with the prediction system decreased, although the system maintained the high positive and negative predictive values (data not shown).

The SFFS algorithm could be modified to include other factors (e.g., mutations in the tumor, patients' clinical characteristics, additional genetic variants, etc.) to improve the prediction performance. Such modifications may result in a system that could meaningfully predict clinical outcomes, including tumor response. Recent advances in technology for sequencing whole genomes of individuals may lead to substantial increases in information that might be useful for personalized therapy. However, such complicated information could not be efficiently or fully utilized in the currently available formats. SFFS could easily construct a system that can utilize huge data sets such as whole-genome sequences. Our strategy for developing SFFS-based systems for clinical use could serve as a powerful tool for advancing personalized therapy, although additional prospective study of this prediction system is needed.
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![Pairwise linkage disequilibrium relationships between the *UGT1A* variants. (A) The Lewontin's coefficient D′ and (B) the correlation coefficient *r*^2^ are represented as values and colors \[in panel A, log of the odds (LOD) ≥2 shades of pink/red, LOD \<2 and D′=1 is blue, and LOD \<2 and D′ \<1 is white. In panel B, *r*^2^\<0.01 is white, 0.01≤*r*^2^ \<0.95 is shades of grey, and *r*^2^≥0.95 is black\] in each box.](IJO-45-04-1381-g00){#f1-ijo-45-04-1381}

![The *UGT1A* genotype combinations that predict the presence or absence of severe irinotecan toxicity based on statistical pattern recognition. (A) A total of 8 combinations (P-I to P-VIII) for positive prediction of the toxicity and (B) 10 combinations (N-I to N-X) for negative prediction are presented. (A) The 8 combinations (P-I to P-VIII) that predict the presence of irinotecan toxicity are shown. (B) The 10 combinations (N-I to N-X) that predict the absence of irinotecan toxicity are shown. Eight factors-patient age, patient gender and genotypes at six *UGT1A* sites \[*UGT1A1\*6*, *\*28*, *\*60*, *1A7* (*387T*\>*G*), *1A7* (*622T*\>*C*) and *1A9\*1b*\] were used with sequential floating forward selection (SFFS) for statistical pattern recognition as described in Materials and methods. Homozygosity for alleles associated with irinotecan toxicity, heterozygosity and homozygosity for alleles not associated with irinotecan toxicity are indicated by red, blue and green cells, respectively. ^\*\*^The un-specified categories (regardless of genotypes, gender or age).](IJO-45-04-1381-g01){#f2-ijo-45-04-1381}

###### 

Characteristics of the patients.

                                 Sub-population (treatment regimen)                                                                                                                                                                      
  ------------------------ ----- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- --------------------------------------------------
  Toxicity of irinotecan                                                                                                                                                                                                                 
   No                      72    20                                                19                                                16                                                17                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   Yes                     51    18                                                16                                                6                                                 11                                                
  Gender                                                                                                                                                                                                                                 
   Male                    78    24                                                24                                                17                                                13                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   Female                  45    14                                                11                                                5                                                 15                                                
  Age                                                                                                                                                                                                                                    
   ≤60                     50    14                                                14                                                9                                                 13                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   \>60                    73    24                                                21                                                13                                                15                                                
  *UGT1A1\*6*                                                                                                                                                                                                                            
   −*/*−                   84    25                                                23                                                15                                                21                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   −*/\*6*                 36    12                                                11                                                6                                                 7                                                 
   *\*6/\*6*               3     1                                                 1                                                 1                                                 0[c](#tfn4-ijo-45-04-1381){ref-type="table-fn"}   
  *UGT1A1\*28*                                                                                                                                                                                                                           
   −*/*−                   103   32                                                27                                                22                                                22                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   −*/\*28*                20    6                                                 8                                                 0[b](#tfn3-ijo-45-04-1381){ref-type="table-fn"}   6                                                 
   *\*28/\*28*             0     0[a](#tfn2-ijo-45-04-1381){ref-type="table-fn"}   0[a](#tfn2-ijo-45-04-1381){ref-type="table-fn"}   0[b](#tfn3-ijo-45-04-1381){ref-type="table-fn"}   0[c](#tfn4-ijo-45-04-1381){ref-type="table-fn"}   
  *UGT1A1\*60*                                                                                                                                                                                                                           
   −*/*−                   71    19                                                21                                                15                                                16                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   −*/\*60*                46    17                                                12                                                6                                                 11                                                
   *\*60/\*60*             6     2                                                 2                                                 1                                                 1                                                 
  *UGT1A7*                                                                                                                                                                                                                               
   387T/T                  41    13                                                12                                                8                                                 8                                                 NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   387T/G                  69    18                                                18                                                13                                                20                                                
   387G/G                  13    7                                                 5                                                 1                                                 0                                                 
  *UGT1A7*                                                                                                                                                                                                                               
   387T/T                  70    21                                                19                                                14                                                16                                                NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   387T/G                  48    15                                                13                                                8                                                 12                                                
   387G/G                  5     2                                                 3                                                 0                                                 0                                                 
  *UGT1A9\*1b*                                                                                                                                                                                                                           
   *\*1b/\*1b*             43    14                                                12                                                9                                                 8                                                 NS[d](#tfn5-ijo-45-04-1381){ref-type="table-fn"}
   −*/\*1b*                67    17                                                18                                                12                                                20                                                
   −*/*−                   13    7                                                 5                                                 1                                                 0                                                 

The following patients were not enrolled in this study as described in Materials and methods.

Patients bearing *UGT1A1\*28* homozygous were excluded from the FLIGHT1 and FLIGHT2 studies.

Homozygous and heterozygous of *UGT1A1\*28* were not enrolled in the FRUTIRI study.

Homozygous of *UGT1A1\*6* and *\*28* and compound heterozygous of *UGT1A1\*6* and *\*28* were not included in the consecutive patients received second-line FOLFILI therapy.

NS, not significant among 4 groups by Fisher's exact test.

###### 

Minor allele frequency and Hardy-Weinberg equilibrium in 123 patients.

                                        103 patients[a](#tfn6-ijo-45-04-1381){ref-type="table-fn"}   123 patients[b](#tfn7-ijo-45-04-1381){ref-type="table-fn"}          
  ------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ------ ------
  *UGT1A1\*6* \[211 (G\>A)\]            0.18                                                         1.00                                                         0.17   1.00
  *UGT1A1\*28* \[(TA)~6~\>(TA)~7~\]     0.12                                                         0.80                                                         0.08   0.86
  *UGT1A1\*60* \[−3279 (T\>G)\]         0.27                                                         0.99                                                         0.24   0.92
  *UGT1A7* \[387 (T\>G)\]               0.42                                                         1.00                                                         0.39   0.07
  *UGT1A7* \[622 (T\>C)\]               0.27                                                         0.61                                                         0.24   0.54
  *UGT1A9\*1b* \[−118 (T~9~\>T~10~)\]   0.41                                                         0.84                                                         0.38   0.13

Patients enrolled in the FLIGHT1, FLIGHT2 and FRUTIRI studies (patients received lower starting dose of irinotecan were not excluded).

Patients subjected to case-control study (patients received lower starting dose of irinotecan were excluded).

MAF, minor allele frequency. HWp, p-value of Hardy-Weinberg equilibrium.

###### 

Haplotype frequency.

  Haplotypes   *UGT1A* alleles                                      Allele frequencies                                                                                                                                                                                                                                                    
  ------------ ---------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- ------- -------
  *Hp-I*       T~10~                                                T                                                 T                                                 T                                                 TA~6~                                                 G                                                 0.524   0.573
  *Hp-II*      T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   C[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   T                                                 TA~6~                                                 A[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   0.170   0.159
  *Hp-III*     T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   T                                                 G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   TA~6~                                                 G                                                 0.131   0.134
  *Hp-IV*      T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   C[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   TA~7~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G                                                 0.063   0.041
  *Hp-V*       T~10~                                                T                                                 T                                                 G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   TA~7~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G                                                 0.044   0.028
  *Hp-VI*      T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   C[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   T                                                 TA~6~                                                 G                                                 0.015   0.016
  *Hp-VII*     T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   C[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   TA~6~                                                 G                                                 0.015   0.012
  *Hp-VIII*    T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   T                                                 G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   TA~7~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G                                                 0.010   0.012
  *Hp-IX*      T~10~                                                T                                                 T                                                 G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   TA~6~                                                 G                                                 0.010   0.008
  *Hp-X*       T~10~                                                G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   C[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   T                                                 TA~6~                                                 A[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   0.010   0.008
  *Hp-XI*      T~9~[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   G[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   T                                                 T                                                 TA~6~                                                 G                                                 0.005   0.004
  *Hp-XII*     T~10~                                                T                                                 T                                                 T                                                 TA~6~                                                 A[a](#tfn9-ijo-45-04-1381){ref-type="table-fn"}   0.005   0.004

Association of the alleles with toxicity of irinotecan.

Patients enrolled in the FLIGHT1, FLIGHT2 and FRUTIRI studies (patients received lower starting dose of irinotecan were not excluded).

Patients subjected to the case-control study (patients received lower starting dose of irinotecan were excluded).

###### 

Associations between *UGT1A* genotypes/haplotypes and irinotecan toxicity.

                                                                                                        Toxicity   p-value                      
  -------------------------------------------------- -------------------------------------------------- ---------- --------- -------- --------- ---------
  Genotypes                                                                                                                                     
   *UGT1A1\*6*                                       −*/*−                                              27         57        (32.1)   0.002     0.001
  −*/\*6*                                            21                                                 15         (58.3)                       
  *\*6/\*6*                                          3                                                  0          (100.0)                      
   *UGT1A1\*28*                                      −*/*−                                              40         63        (38.8)   0.218     \-
  −*/1\*28*                                          11                                                 9          (55.0)                       
  *1\*28/1\*28*                                      \-                                                 \-         \-                           
   *UGT1A1\*60*                                      −*/*−                                              27         44        (38.0)   0.349     0.219
  −*/1\*60*                                          20                                                 26         (43.5)                       
  *1\*60/1\*60*                                      4                                                  2          (66.7)                       
   *UGT1A7* (387T\>G)                                387T/T                                             9          32        (22.0)   0.005     0.002
  387T/G                                             34                                                 35         (49.3)                       
  387G/G                                             8                                                  5          (61.5)                       
   *UGT1A7* (622T\>C)                                622T/T                                             18         52        (25.7)   \<0.001   \<0.001
  622T/C                                             31                                                 17         (64.6)                       
  622C/C                                             2                                                  3          (40.0)                       
   *UGT1A9\*1b*                                      *9\*1b/9\*1b*                                      9          34        (20.9)   0.003     0.001
  −*/9\*1b*                                          34                                                 33         (50.7)                       
  −*/*−                                              8                                                  5          (61.5)                       
  Haplotypes                                                                                                                                    
   *Hp-I*                                            0[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   12         6         (66.7)   0.002     \<0.001
  1[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   32                                                 37         (46.4)                       
  2[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   7                                                  29         (19.4)                       
   *Hp-II*                                           0[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   27         59        (31.4)   0.001     \<0.001
  1[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   22                                                 13         (62.9)                       
  2[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   2                                                  0          (100.0)                      
   *Hp-III*                                          0[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   38         53        (41.8)   0.517     0.900
  1[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   12                                                 19         (38.7)                       
  2[a](#tfn12-ijo-45-04-1381){ref-type="table-fn"}   1                                                  0          (100.0)                      
  Clinical features                                                                                                                             
   Gender                                            Male                                               31         47        (39.7)   0.705     \-
  Female                                             20                                                 25         (44.4)                       
   Age                                               ≤60                                                15         35        (30.0)   0.027     \-
  \>60                                               36                                                 37         (49.3)                       

Number of alleles carried by the patient.

CA, Cochran-Armitage trend test.

###### 

Predicitive performance for irinotecan toxicity by the genotype combinations.

                                                                                Training (n=73)   Validation (n=50)           
  ----------------------------------------------------------------------------- ----------------- ------------------- ------- --------
  Matched with the combination[a](#tfn14-ijo-45-04-1381){ref-type="table-fn"}   62/73             (84.9)              43/50   (86.0)
   Accuracy in applied patients                                                 52/62             (83.9)              31/43   (72.1)
   Positive predictive value[b](#tfn15-ijo-45-04-1381){ref-type="table-fn"}     19/22             (86.4)              7/10    (70.0)
   Negative predictive value[b](#tfn15-ijo-45-04-1381){ref-type="table-fn"}     33/40             (82.5)              24/33   (72.7)
  Accuracy                                                                      52/73             (71.2)              31/50   (62.0)
  Sensitivity                                                                   19/34             (55.9)              7/17    (41.2)
  Specificity                                                                   33/39             (84.6)              24/33   (72.7)

The combination consists of 8 factors; 6 genotypes \[*UGT1A1\*6*, *UGT1A1\*28*, *UGT1A1\*60*, *UGT1A7* (387T\>G), *UGT1A7* (622T\>C) and *UGT1A9\*1b*\], gender and age.

Prediction of severe toxicity is positive and prediction of no severe toxicity is negative.

###### 

Associations between UGT1A genotypes/haplotypes and irinotecan toxicity in training and validation sub-populations.

                                                                          Training (n=73)   Validation (n=50)                                                                                                                                                                              
  ----------------------------------------------------------------------- ----------------- ------------------- -------- -------------------------------------------------- --------------- ------- ---- ---- -------- -------------------------------------------------- ---------------- -------
  Haplotypes                                                                                                                                                                                                                                                                               
   *Hp-I* (+/+)                                                           5                 15                  (25.0)   1[c](#tfn18-ijo-45-04-1381){ref-type="table-fn"}                           2    14   (12.5)   1[c](#tfn18-ijo-45-04-1381){ref-type="table-fn"}                    
   *Hp-I* (−/−, −/+)                                                      29                24                  (54.7)   3.63                                               (1.15--11.42)   0.035   15   19   (44.1)   5.53                                               (1.08--28.18)    0.053
   *Hp-II* (+/+,−/+)                                                      16                8                   (66.7)   0.64                                               (1.60--22.48)   0.008   8    5    (61.5)   11.20                                              (1.75--71.64)    0.016
  The predicition system[a](#tfn16-ijo-45-04-1381){ref-type="table-fn"}                                                                                                                                                                                                                    
   Negative for toxicity                                                  7                 33                  (17.5)   0.64                                               (0.17--2.34)    0.511   9    24   (27.3)   2.63                                               (0.50--13.92)    0.300
   Positive for toxicity                                                  19                3                   (86.4)   8.00                                               (1.51--42.45)   0.021   7    3    (70.0)   16.33                                              (2.20--121.43)   0.009
   Not matched[b](#tfn17-ijo-45-04-1381){ref-type="table-fn"}             8                 3                   (72.7)                                                                              1    6    (14.3)                                                                       
  Genotypes                                                                                                                                                                                                                                                                                
   *UGT1A1\*6* (+/+,−/+)                                                  16                9                   (64.0)   5.33                                               (1.45--19.58)   0.016   8    6    (57.1)   9.33                                               (1.51--57.65)    0.019
   *UGT1A1\*28* (−/+)                                                     7                 7                   (50.0)   3.00                                               (0.70--12.88)   0.163   4    2    (66.7)   14.00                                              (1.47--133.23)   0.025
   *UGT1A1\*60* (+/+,−/+)                                                 18                15                  (54.5)   3.60                                               (1.06--12.22)   0.048   6    13   (31.6)   3.23                                               (0.55--18.96)    0.244
   *UGT1A7* (387G/G, T/G)                                                 27                21                  (56.3)   3.86                                               (1.21--12.33)   0.032   15   19   (44.1)   5.53                                               (1.08--28.18)    0.053
   *UGT1A7* (622C/C, T/C)                                                 20                13                  (60.6)   4.62                                               (1.35--15.78)   0.022   13   7    (65.0)   13.00                                              (2.27--74.32)    0.002
   *UGT1A9\*1b* (−/−, −/+)                                                27                20                  (57.4)   4.05                                               (1.26--12.99)   0.018   15   18   (45.5)   5.83                                               (1.14--29.84)    0.028

The prediction system consisted of the combinations of 8 factors (6 genotypes, gender and age).

In training and validation populations, 9/73 (12.3%) and 7/50 (14.0%) patients were not matched with the combinations of the prediction system.

Reference category.
